Peptide LibraryResearch statistics
Motixafortide research: publications and trials
At a glance
Publications, all years
29
Since 2010
Publications in 2026 so far
4
Through November 1, 2026
Human clinical research
37.9%
11 of 29 classified
Registered clinical trials
22
ClinicalTrials.gov
Randomized controlled trials
5
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
37.9%
6 animal · 4 in vitro · 1 computational
Records that only mention it
20
Not counted above
Status in the library: FDA-approved.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Motixafortide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2010 | 0 | 1 | 0 | 0 | 1 |
| 2012 | 0 | 1 | 0 | 1 | 2 |
| 2013 | 1 | 2 | 0 | 0 | 3 |
| 2014 | 0 | 2 | 0 | 0 | 2 |
| 2015 | 0 | 1 | 0 | 0 | 1 |
| 2017 | 1 | 1 | 0 | 0 | 2 |
| 2019 | 1 | 0 | 0 | 0 | 1 |
| 2020 | 2 | 0 | 0 | 0 | 2 |
| 2021 | 1 | 0 | 0 | 0 | 1 |
| 2023 | 1 | 1 | 2 | 2 | 6 |
| 2024 | 0 | 0 | 1 | 1 | 2 |
| 2025 | 0 | 2 | 0 | 0 | 2 |
| 2026 (to date) | 4 | 0 | 0 | 0 | 4 |
Study types
| Animal study | 6 |
|---|---|
| Other clinical trial | 5 |
| Randomized controlled trial | 5 |
| In vitro study | 4 |
| Editorial, letter or other | 3 |
| Review | 3 |
| Computational study | 1 |
| Correction or retraction notice | 1 |
| Observational human study | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Oncology | 24 |
|---|---|
| Immune system | 11 |
| Cardiovascular | 6 |
| Endocrinology | 4 |
| Gastrointestinal | 4 |
| Tissue repair | 2 |
| Neurological and mental health | 1 |
Registered clinical trials
5 of 11 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 11 · Recruiting: 4 · Terminated: 3 · Active, not recruiting: 2 · Unknown status: 1 · Withdrawn: 1
Phase 1: 6 · Phase 1 / Phase 2: 5 · Phase 2: 9 · Phase 3: 2
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.
Blood · July 1, 2026 · Randomized controlled trial · cited 1 times · open access
PMID 41980027 · DOI 10.1182/blood.2025032033 · Human clinical research
- Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.
The oncologist · March 1, 2026 · Randomized controlled trial · cited 1 times · open access
PMID 41741368 · DOI 10.1093/oncolo/oyag023 · Human clinical research
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
Nature medicine · April 17, 2023 · Randomized controlled trial · cited 81 times · open access
PMID 37069359 · DOI 10.1038/s41591-023-02273-z · Human clinical research
- GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.
Future oncology (London, England) · September 9, 2019 · Randomized controlled trial · cited 25 times · open access
PMID 31495201 · DOI 10.2217/fon-2019-0380 · Human clinical research
- Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers.
Clinical cancer research : an official journal of the American Association for Cancer Research · August 23, 2017 · Randomized controlled trial · cited 52 times
PMID 28835380 · DOI 10.1158/1078-0432.ccr-16-2919 · Human clinical research
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.
Nature communications · August 21, 2026 · Other clinical trial · cited 0 times · open access
PMID 42811017 · DOI 10.1038/s41467-026-76559-4 · Human clinical research
- Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · July 12, 2021 · Other clinical trial · cited 92 times
PMID 34253578 · DOI 10.1158/1078-0432.ccr-21-0929 · Human clinical research
- BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Cancer · December 3, 2020 · Other clinical trial · cited 43 times · open access
PMID 33270904 · DOI 10.1002/cncr.33338 · Human clinical research
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Nature medicine · May 25, 2020 · Other clinical trial · cited 557 times
PMID 32451495 · DOI 10.1038/s41591-020-0880-x · Human clinical research
- The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research · November 18, 2013 · Other clinical trial · cited 87 times
PMID 24246358 · DOI 10.1158/1078-0432.ccr-13-1302 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Nature medicine · May 25, 2020 · Other clinical trial · cited 557 times
PMID 32451495 · DOI 10.1038/s41591-020-0880-x · Human clinical research
- The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
Leukemia · March 10, 2017 · In vitro study · cited 111 times
PMID 28280274 · DOI 10.1038/leu.2017.82 · In vitro studies
- Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · July 12, 2021 · Other clinical trial · cited 92 times
PMID 34253578 · DOI 10.1158/1078-0432.ccr-21-0929 · Human clinical research
- CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.
Experimental hematology · December 5, 2010 · Animal study · cited 92 times
PMID 21138752 · DOI 10.1016/j.exphem.2010.11.010 · Animal studies
- The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research · November 18, 2013 · Other clinical trial · cited 87 times
PMID 24246358 · DOI 10.1158/1078-0432.ccr-13-1302 · Human clinical research
Latest publications
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.
Nature communications · August 21, 2026 · Other clinical trial · cited 0 times · open access
PMID 42811017 · DOI 10.1038/s41467-026-76559-4 · Human clinical research
- Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience.
Transfusion · July 11, 2026 · Observational human study · cited 0 times
PMID 42435378 · DOI 10.1111/trf.70260 · Human clinical research
- Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.
Blood · July 1, 2026 · Randomized controlled trial · cited 1 times · open access
PMID 41980027 · DOI 10.1182/blood.2025032033 · Human clinical research
- Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.
The oncologist · March 1, 2026 · Randomized controlled trial · cited 1 times · open access
PMID 41741368 · DOI 10.1093/oncolo/oyag023 · Human clinical research
- A human iPSC-based neural spheroid platform for modelling glioblastoma infiltration using high-content imaging.
Scientific reports · December 13, 2025 · In vitro study · cited 2 times · open access
PMID 41390851 · DOI 10.1038/s41598-025-30914-5 · In vitro studies
- Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma.
Biomedical chromatography : BMC · July 1, 2025 · Animal study · cited 1 times
PMID 40420423 · DOI 10.1002/bmc.70126 · Animal studies
- A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · April 17, 2024 · Review · cited 2 times
PMID 38629183 · DOI 10.1177/10781552241247472 · Reviews and meta-analyses
- Motixafortide Acetate.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · January 1, 2024 · Editorial, letter or other · cited 0 times
PMID 37862457 · DOI 10.1093/ajhp/zxad253 · Commentary and other
- Correction to: Motixafortide: First Approval.
Drugs · December 1, 2023 · Correction or retraction notice · cited 1 times · open access
PMID 38060093 · DOI 10.1007/s40265-023-01984-4 · Notices
- Motixafortide: First Approval.
Drugs · November 1, 2023 · Review · cited 45 times · open access
PMID 37996648 · DOI 10.1007/s40265-023-01962-w · Reviews and meta-analyses
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Aphexda; BKT140; BL-8040; Motixafortide
((TITLE_ABS:"Aphexda" OR CHEM:"Aphexda") OR (TITLE_ABS:"BKT140" OR CHEM:"BKT140" OR TITLE_ABS:"BKT 140" OR CHEM:"BKT 140") OR (TITLE_ABS:"BL-8040" OR CHEM:"BL-8040" OR TITLE_ABS:"BL8040" OR CHEM:"BL8040") OR (TITLE_ABS:"Motixafortide" OR CHEM:"Motixafortide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Motixafortide research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/motixafortide